| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Intensive Care Medicine, University Hospital Gasthuisberg, University of Leuven (G.V.d.B., F.W., P.W.), B-3000 Leuven, Belgium; Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney University (R.C.B.), St. Leonards, New South Wales 2065, Australia; the Department of Medicine, Division of Endocrinology, Tulane University Medical Center (C.Y.B.), New Orleans, Louisiana 70112-2699; and the General Clinical Research Center and Department of Medicine, Division of Endocrinology, University of Virginia Health Sciences Center (J.D.V.), Charlottesville, Virginia 29908
Address all correspondence and requests for reprints to: Greet Van den Berghe, M.D., Ph.D., Department of Intensive Care Medicine University Hospital Gasthuisberg, University of Leuven, B-3000 Leuven, Belgium. E-mail: greta.vandenberghe{at}uz.kuleuven.ac.be
Female gender appears to protect against adverse outcome from prolonged critical illness, a condition characterized by blunted and disorderly GH secretion and impaired anabolism. As a sexual dimorphism in the GH secretory pattern of healthy humans and rodents determines gender differences in metabolism, we here compared GH secretion and responsiveness to GH secretagogues in male and female protracted critically ill patients. GH secretion was quantified by deconvolution analysis and approximate entropy estimates of 9-h nocturnal time series in 9 male and 9 female patients matched for age (mean ± SD, 67 ± 11 and 67 ± 15 yr), body mass index, severity and duration of illness, feeding, and medication. Serum concentrations of PRL, TSH, cortisol, and sex steroids were measured concomitantly. Serum levels of GH-binding protein, insulin-like growth factor I (IGF-I), IGF-binding proteins (IGFBPs), and PRL were compared with those of 50 male and 50 female community-living control subjects matched for age and body mass index. In a second study, GH responses to GHRH (1 µg/kg), GH-releasing peptide-2 (GHRP-2; 1 µg/kg) and GHRH plus GHRP-2 (1 and 1 µg/kg) were examined in comparable, carefully matched male (n = 15) and female (n = 15) patients.
Despite identical mean serum GH concentrations, total GH output, GH half-life, and number of GH pulses, critically ill men paradoxically presented with less pulsatile (mean ± SD pulsatile GH fraction, 39 ± 14% vs. 67 ± 20%; P = 0.002) and more disorderly (approximate entropy, 0.946 ± 0.113 vs. 0.805 ± 0.147; P = 0.02) GH secretion than women. Serum IGF-I, IGFBP-3, and acid-labile subunit (ALS) levels were low in patients compared with controls, with male patients revealing lower IGF-I (P = 0.01) and ALS (P = 0.005) concentrations than female patients. Correspondingly, circulating IGF-I and ALS levels correlated positively with pulsatile (but not with nonpulsatile) GH secretion. Circulating levels of GH-binding protein and IGFBP-1, -2, and -6 were higher in patients than controls, without a detectable gender difference. In female patients, PRL levels were 3-fold higher, and TSH and cortisol tended to be higher than levels in males. In both genders, estrogen levels were more than 3-fold higher than normal, and testosterone (2.25 ± 1.94 vs. 0.97 ± 0.39 nmol/L; P = 0.03) and dehydroepiandrosterone sulfate concentrations were low. In male patients, low testosterone levels were related to reduced GH pulse amplitude (r = 0.91; P = 0.0008). GH responses to GHRH were relatively low and equal in critically ill men and women (7.3 ± 9.4 vs. 7.8 ± 4.1 µg/L; P = 0.99). GH responses to GHRP-2 in women (93 ± 38 µg/L) were supranormal and higher (P < 0.0001) than those in men (28 ± 16 µg/L). Combining GHRH with GHRP-2 nullified this gender difference (77 ± 58 in men vs. 120 ± 69 µg/L in women; P = 0.4).
In conclusion, a paradoxical gender dissociation within the GH/IGF-I axis is evident in protracted critical illness, with men showing greater loss of pulsatility and regularity within the GH secretory pattern than women (despite indistinguishable total GH output) and concomitantly lower IGF-I and ALS levels. Less endogenous GHRH action in severely ill men compared with women, possibly due to profound hypoandrogenism, accompanying loss of the putative endogenous GHRP-like ligand action with prolonged stress in both genders may explain these novel findings.
This article has been cited by other articles:
![]() |
M. Maggio, F. Lauretani, G. P. Ceda, S. Bandinelli, S. M. Ling, E. J. Metter, A. Artoni, L. Carassale, A. Cazzato, G. Ceresini, et al. Relationship Between Low Levels of Anabolic Hormones and 6-Year Mortality in Older Men: The Aging in the Chianti Area (InCHIANTI) Study Arch Intern Med, November 12, 2007; 167(20): 2249 - 2254. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Lang, R. A. Frost, and T. C. Vary Skeletal muscle protein synthesis and degradation exhibit sexual dimorphism after chronic alcohol consumption but not acute intoxication Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1497 - E1506. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K Gleeson and S. M Shalet GH responsiveness varies during the menstrual cycle Eur. J. Endocrinol., December 1, 2005; 153(6): 775 - 779. [Abstract] [Full Text] [PDF] |
||||
![]() |
M A Spruit, M J Thomeer, R Gosselink, T Troosters, A Kasran, A J T Debrock, M G Demedts, and M Decramer Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status Thorax, January 1, 2005; 60(1): 32 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Veldhuis, J. T. Patrie, K. T. Brill, J. Y. Weltman, E. E. Mueller, C. Y. Bowers, and A. Weltman Contributions of Gender and Systemic Estradiol and Testosterone Concentrations to Maximal Secretagogue Drive of Burst-Like Growth Hormone Secretion in Healthy Middle-Aged and Older Adults J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6291 - 6296. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mesotten, P. J. Wouters, R. P. Peeters, K. V. Hardman, J. M. Holly, R. C. Baxter, and G. Van den Berghe Regulation of the Somatotropic Axis by Intensive Insulin Therapy during Protracted Critical Illness J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3105 - 3113. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baron-Hay, F. Boyle, A. Ferrier, and C. Scott Elevated Serum Insulin-Like Growth Factor Binding Protein-2 as a Prognostic Marker in Patients with Ovarian Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1796 - 1806. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Lissett and S. M. Shalet The Impact of Dose and Route of Estrogen Administration on the Somatotropic Axis in Normal Women J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4668 - 4672. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mesotten, P. J. D. Delhanty, F. Vanderhoydonc, K. V. Hardman, F. Weekers, R. C. Baxter, and G. van den Berghe Regulation of Insulin-Like Growth Factor Binding Protein-1 during Protracted Critical Illness J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5516 - 5523. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sharma Extolling the Virtues of Euglycemia Clin. Diabetes, April 1, 2002; 20(2): 87 - 88. [Full Text] [PDF] |
||||
![]() |
F. Weekers, E. Van Herck, W. Coopmans, M. Michalaki, C. Y. Bowers, J. D. Veldhuis, and G. Van den Berghe A Novel in Vivo Rabbit Model of Hypercatabolic Critical Illness Reveals a Biphasic Neuroendocrine Stress Response Endocrinology, March 1, 2002; 143(3): 764 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Cohen, G. M. Bright, A. D. Rogol, A.-M. Kappelgaard, and R. G. Rosenfeld Effects of Dose and Gender on the Growth and Growth Factor Response to GH in GH-Deficient Children: Implications for Efficacy and Safety J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 90 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. van den Berghe, P. Wouters, F. Weekers, C. Verwaest, F. Bruyninckx, M. Schetz, D. Vlasselaers, P. Ferdinande, P. Lauwers, and R. Bouillon Intensive Insulin Therapy in Critically Ill Patients N. Engl. J. Med., November 8, 2001; 345(19): 1359 - 1367. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Van den Berghe, F. Weekers, R. C. Baxter, P. Wouters, A. Iranmanesh, R. Bouillon, and J. D. Veldhuis Five-Day Pulsatile Gonadotropin-Releasing Hormone Administration Unveils Combined Hypothalamic-Pituitary-Gonadal Defects Underlying Profound Hypoandrogenism in Men with Prolonged Critical Illness J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3217 - 3226. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |